SXTC VS GLMD Stock Comparison

Performance

SXTC
10/100

SXTC returned -87.22% in the last 12 months. Based on SPY's performance of -11.50%, its performance is below average giving it a score of 10 of 100.

GLMD
10/100

GLMD returned -92.16% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

SXTC
21/100

SXTC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

GLMD
43/100

GLMD receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Profit

SXTC
63/100

Out of the last 8 quarters, SXTC has had 7 profitable quarters and has increased their profits year over year on 2 of them.

GLMD
10/100

Out of the last 20 quarters, GLMD has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SXTC
40/100

SXTC has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

GLMD
44/100

GLMD has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

SXTC

"Analyst Price Targets" not found for SXTC

GLMD
75/100

5 analysts offer 12-month price targets for GLMD. Together, they have an average target of 0, the most optimistic target put GLMD at 0 within 12-months and the most pessimistic has GLMD at 0.

Earnings

SXTC

"Earnings" not found for SXTC

GLMD
10/100

GLMD has missed earnings 6 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

China SXT Pharmaceuticals, Inc. Ordinary Shares Summary

Nasdaq / SXTC

Healthcare

Drug Manufacturers - Specialty & Generic

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

Galmed Pharmaceuticals Ltd. Summary

Nasdaq / GLMD

Healthcare

Biotechnology

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Power up your portfolio